CL2023000916A1 - Anticuerpos con capacidad de unirse a ror2 y anticuerpos biespecíficos que se unen a ror2 y cd3. - Google Patents
Anticuerpos con capacidad de unirse a ror2 y anticuerpos biespecíficos que se unen a ror2 y cd3.Info
- Publication number
- CL2023000916A1 CL2023000916A1 CL2023000916A CL2023000916A CL2023000916A1 CL 2023000916 A1 CL2023000916 A1 CL 2023000916A1 CL 2023000916 A CL2023000916 A CL 2023000916A CL 2023000916 A CL2023000916 A CL 2023000916A CL 2023000916 A1 CL2023000916 A1 CL 2023000916A1
- Authority
- CL
- Chile
- Prior art keywords
- ror2
- bind
- antibodies
- ability
- bispecific antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20199893 | 2020-10-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023000916A1 true CL2023000916A1 (es) | 2023-11-24 |
Family
ID=72744675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023000916A CL2023000916A1 (es) | 2020-10-02 | 2023-03-29 | Anticuerpos con capacidad de unirse a ror2 y anticuerpos biespecíficos que se unen a ror2 y cd3. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230365714A1 (https=) |
| EP (1) | EP4221742A1 (https=) |
| JP (1) | JP2023547329A (https=) |
| KR (1) | KR20230080437A (https=) |
| CN (1) | CN116438198A (https=) |
| AU (1) | AU2021351187A1 (https=) |
| BR (1) | BR112023005742A2 (https=) |
| CA (1) | CA3193914A1 (https=) |
| CL (1) | CL2023000916A1 (https=) |
| CO (1) | CO2023005044A2 (https=) |
| IL (1) | IL301513A (https=) |
| MX (1) | MX2023003749A (https=) |
| WO (1) | WO2022069724A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4642808A2 (en) * | 2022-12-30 | 2025-11-05 | The Regents of the University of California | Anti-ror-2 antibodies and methods of use |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077A (en) | 1849-01-30 | Improved hinged claw-wrench | ||
| US835A (en) | 1838-07-12 | X i i i x | ||
| US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| WO2000046147A2 (en) | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| DK2314629T4 (da) | 2002-07-18 | 2023-02-06 | Merus Nv | Rekombinant produktion af blandinger af antistoffer |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CA2631184A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| CA2646508A1 (en) | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| EP2158221B1 (en) | 2007-06-21 | 2018-08-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| JP5397668B2 (ja) | 2008-09-02 | 2014-01-22 | ソニー株式会社 | 記憶素子および記憶装置 |
| DK2786762T3 (da) | 2008-12-19 | 2019-05-06 | Macrogenics Inc | Kovalente diabodies og anvendelser deraf |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| CN102770456B (zh) | 2009-12-04 | 2018-04-06 | 弗·哈夫曼-拉罗切有限公司 | 多特异性抗体、抗体类似物、组合物和方法 |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| CN103261220B (zh) | 2010-08-16 | 2016-06-15 | 诺夫免疫股份有限公司 | 用于生成多特异性和多价抗体的方法 |
| CN103068847B (zh) | 2010-08-24 | 2019-05-07 | 罗切格利卡特公司 | 可活化的双特异性抗体 |
| CN103068846B9 (zh) | 2010-08-24 | 2016-09-28 | 弗·哈夫曼-拉罗切有限公司 | 包含二硫键稳定性Fv片段的双特异性抗体 |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| US9615326B2 (en) * | 2011-06-30 | 2017-04-04 | Intel Corporation | System and method of improving power efficiency in wireless communication system |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| SG11201401422VA (en) | 2011-10-27 | 2014-09-26 | Genmab As | Production of heterodimeric proteins |
| RS60499B1 (sr) | 2011-12-20 | 2020-08-31 | Medimmune Llc | Modifikovani polipeptidi za bispecifične skelete antitela |
| US20140322234A1 (en) * | 2012-01-03 | 2014-10-30 | The Board Of Trustees Of The Leland Stanford Junior University | Analysis and Targeting of ROR2 in Cancer |
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| CN104736174B (zh) | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| US9683044B2 (en) | 2012-08-20 | 2017-06-20 | Gliknik Inc. | Molecules with antigen binding and polyvalent FC gamma receptor binding activity |
| KR20200024345A (ko) | 2013-01-10 | 2020-03-06 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
| ME03675B (me) | 2013-07-05 | 2020-10-20 | Genmab As | Humanizovana ili himerna anтi-cd3 antiтela |
| CA2945882A1 (en) | 2014-04-16 | 2015-10-22 | Ucb Biopharma Sprl | Multimeric fc proteins |
| US11673957B2 (en) * | 2015-03-10 | 2023-06-13 | Eureka Therapeutics, Inc. | Anti-ROR2 antibodies |
| IL256562B2 (en) * | 2015-07-15 | 2024-07-01 | Genmab As | Human CD3 antibodies or chimeras |
-
2021
- 2021-10-01 JP JP2023520046A patent/JP2023547329A/ja active Pending
- 2021-10-01 MX MX2023003749A patent/MX2023003749A/es unknown
- 2021-10-01 CA CA3193914A patent/CA3193914A1/en active Pending
- 2021-10-01 BR BR112023005742A patent/BR112023005742A2/pt unknown
- 2021-10-01 KR KR1020237014162A patent/KR20230080437A/ko active Pending
- 2021-10-01 EP EP21786867.8A patent/EP4221742A1/en active Pending
- 2021-10-01 CN CN202180067909.7A patent/CN116438198A/zh active Pending
- 2021-10-01 WO PCT/EP2021/077130 patent/WO2022069724A1/en not_active Ceased
- 2021-10-01 IL IL301513A patent/IL301513A/en unknown
- 2021-10-01 AU AU2021351187A patent/AU2021351187A1/en active Pending
- 2021-10-01 US US18/029,472 patent/US20230365714A1/en active Pending
-
2023
- 2023-03-29 CL CL2023000916A patent/CL2023000916A1/es unknown
- 2023-04-21 CO CONC2023/0005044A patent/CO2023005044A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230080437A (ko) | 2023-06-07 |
| JP2023547329A (ja) | 2023-11-10 |
| CA3193914A1 (en) | 2022-04-07 |
| BR112023005742A2 (pt) | 2023-05-02 |
| WO2022069724A1 (en) | 2022-04-07 |
| CO2023005044A2 (es) | 2023-05-19 |
| IL301513A (en) | 2023-05-01 |
| AU2021351187A1 (en) | 2023-04-20 |
| MX2023003749A (es) | 2023-04-24 |
| EP4221742A1 (en) | 2023-08-09 |
| US20230365714A1 (en) | 2023-11-16 |
| CN116438198A (zh) | 2023-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22080714A (es) | Anticuerpos que se unen a b7h4 | |
| CO2020012524A2 (es) | Anticuerpos | |
| DOP2019000280A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
| ECSP21026339A (es) | Anticuerpos antihlag, composiciones que comprenden anticuerpos antihlag y métodos de uso de anticuerpos antihlag | |
| CL2019001198A1 (es) | Anticuerpo bioespecífico contra bcma y cd3 y un fármaco inmunológico para uso combinado en el tratamiento de mieloma múltiple. | |
| CL2017003261A1 (es) | Factor xi anticuerpos y métodos de uso | |
| CO2022002573A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| CL2021001813A1 (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r. | |
| CO2023002375A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| MX2023009100A (es) | Agentes aglutinantes y métodos para usar los mismos. | |
| CL2023000916A1 (es) | Anticuerpos con capacidad de unirse a ror2 y anticuerpos biespecíficos que se unen a ror2 y cd3. | |
| MX2024011128A (es) | Molecula de union a antigeno que se une especificamente a gprc5d y cd3 y su uso medico. | |
| DOP2021000215A (es) | Tratamiento de la cefalea usando anticuerpo anti-cgrp | |
| MX2022006941A (es) | Epítopos de y anticuerpos contra trpv1. | |
| MX2023012351A (es) | Composiciones farmaceuticas que comprenden anticuerpos biespecificos que se unen al inhibidor de la activacion de celulas t que contiene un dominio v-set 1 (b7h4) y cumulo de diferenciacion 3 (cd3). | |
| CL2025002693A1 (es) | Anticuerpos multiespecíficos anti-cd3 y métodos de uso. | |
| CL2025002685A1 (es) | Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso. | |
| MX2025010218A (es) | Anticuerpos multiespecificos anti-cldn6 y anti-cd3 y metodos de uso | |
| CO2026000739A2 (es) | Anticuerpos que se unen a la proteína de activación de fibroblastos alfa y al receptor de muerte 4 | |
| CO2025013101A2 (es) | Anticuerpos multiespecíficos anti–cd3 y métodos de uso |